Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/205420
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRouaz El Hajoui, Khadija-
dc.contributor.authorGarcía Montoya, Encarnación-
dc.contributor.authorLópez Urbano, Andrea-
dc.contributor.authorRomero Obon, Miquel-
dc.contributor.authorChiclana Rodríguez, Blanca-
dc.contributor.authorFraschi Nieto, Alex-
dc.contributor.authorNardi Ricart, Anna-
dc.contributor.authorSuñé Pou, Marc-
dc.contributor.authorSuñé Negre, Josep María-
dc.contributor.authorPérez Lozano, Pilar-
dc.date.accessioned2024-01-09T10:56:29Z-
dc.date.available2024-01-09T10:56:29Z-
dc.date.issued2023-11-04-
dc.identifier.issn1999-4923-
dc.identifier.urihttp://hdl.handle.net/2445/205420-
dc.description.abstractLiquid formulations are mostly used in the paediatric population. However, with certain active pharmaceutical ingredients (APIs), it is very difficult to guarantee quality and stability; this is the case, for example, with omeprazole. Omeprazole is used as a model drug due to the lack of a paediatric formulation meeting gastro-resistance requirements, which remains a challenge today. In this experimental study, the development of enteric polymer-coated pellets is proposed. It is proposed to use aqueous coating dispersions without the use of organic solvents, which are commonly used in fluidised bed coatings. To do this, the design of experiments method is used as a statistical tool for experiment creation and the subsequent analysis of the responses. In particular, this study uses a randomised full factorial design. The mean weight increases of the protective layer and the enteric coating are chosen as factors. Each factor is assigned two levels. Therefore, the design of the used experiments is a 22 + 1 central point. Overall, the obtained pellets can be an alternative to the compounding formulas of omeprazole that are currently used in the paediatric population, which do not meet the gastro-resistance specifications necessary to guarantee the therapeutic efficacy of this active ingredient.-
dc.format.extent18 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics15112587-
dc.relation.ispartofPharmaceutics, 2023, vol. 15, num. 11-
dc.relation.urihttps://doi.org/10.3390/pharmaceutics15112587-
dc.rightscc by (c) Rouaz El Hajoui, Khadija et al, 2023-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationOmeprazol-
dc.subject.classificationPediatria-
dc.subject.otherOmeprazole-
dc.subject.otherPediatrics-
dc.titleOptimisation of the Manufacturing Process of Organic-Solvent-Free Omeprazole Enteric Pellets for the Paediatric Population: Full Factorial Design-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2024-01-09T10:17:19Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid38004567-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
pharmaceutics-15-02587-v2.pdf2.84 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons